Oral Micronized Progesterone Cost in New Hampshire (2026)

What Does Oral Micronized Progesterone Actually Cost in New Hampshire?

The price you pay depends on whether you fill brand-name Prometrium, a generic equivalent, or a compounded formulation. Generic oral micronized progesterone 200 mg capsules average $45 per month at New Hampshire retail pharmacies in 2026. Brand Prometrium, still manufactured by the original Solvay line (now under AbbVie), carries a manufacturer list price of $180 per month. Compounded oral micronized progesterone through a licensed 503A pharmacy costs roughly $25 per month.

These numbers represent a 30-day supply at the standard 200 mg nightly dose used for endometrial protection during estrogen therapy. The FDA-approved labeling for Prometrium specifies 200 mg daily for 12 consecutive days per 28-day cycle in combination with conjugated estrogens. For women on continuous combined HRT, many clinicians prescribe 100 to 200 mg nightly without a cyclic break, a practice supported by data from the PEPI trial [1].

The gap between the $180 list price and the $45 generic price reflects a market that has been genericized for over a decade. Multiple manufacturers produce FDA-approved generic micronized progesterone capsules, and pharmacy benefit managers negotiate rates well below list. Still, $45 per month without insurance adds up to $540 per year. That makes exploring coverage options, discount cards, and compounding worth the effort.

Does New Hampshire Medicaid Cover Oral Micronized Progesterone?

No. New Hampshire Medicaid does not cover oral micronized progesterone when prescribed for endometrial protection on hormone replacement therapy. This gap affects roughly 180,000 Granite Staters enrolled in Medicaid managed care plans administered through the New Hampshire Department of Health and Human Services.

The exclusion applies specifically to the HRT indication. If progesterone is prescribed for other FDA-approved uses (secondary amenorrhea, for example), coverage determination follows standard formulary review. The distinction matters. A provider submitting a claim coded for menopause-related HRT will receive a denial, while the same drug coded for amenorrhea may be approved.

For Medicaid enrollees who need endometrial protection, the practical alternatives are limited. The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy states that "progestogen should be added to estrogen therapy in women with an intact uterus to prevent endometrial hyperplasia." This is not optional care. It is a safety requirement when estrogen is prescribed.

Options for Medicaid patients in New Hampshire include requesting a formulary exception with supporting clinical documentation, switching to a covered synthetic progestin (medroxyprogesterone acetate is on most state Medicaid formularies), or using a 503A compounded product at the $25 per month cash price. The compounded route may actually be cheaper than a Medicaid copay on a covered alternative, depending on the managed care organization.

Generic vs. Brand vs. Compounded: Which Should You Choose?

The clinical answer is straightforward. FDA-approved generic micronized progesterone is bioequivalent to brand Prometrium and costs 75% less. The PEPI trial (N=875) used oral micronized progesterone at 200 mg per day for 12 days per cycle and demonstrated effective endometrial protection with a more favorable lipid profile than medroxyprogesterone acetate [1]. That trial established the clinical foundation for micronized progesterone's role in HRT, and both brand and generic formulations deliver the same active compound.

Compounded progesterone is a different calculation. At $25 per month, it is the cheapest option. But compounded products are not FDA-approved, not subject to the same bioequivalence testing, and not regulated under the same manufacturing standards as commercial generics. The FDA has issued multiple warnings about variability in compounded hormone preparations. A 2001 analysis published in Obstetrics & Gynecology found that compounded progesterone capsules had dose variability ranging from 67.5% to 268.4% of the labeled amount [2].

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has noted: "FDA-approved formulations of micronized progesterone should be preferred over compounded products whenever possible, given the lack of quality assurance with compounding."

For most New Hampshire patients, the generic at $45 per month represents the best balance of cost, quality, and regulatory oversight. Compounded progesterone makes sense primarily when a patient needs a dose or formulation not commercially available (vaginal suppositories at non-standard strengths, for instance) or has a documented peanut allergy, since Prometrium and its generics use peanut oil as a suspension vehicle.

Which Insurance Plans Cover Oral Micronized Progesterone in NH?

Most commercial insurance plans sold in New Hampshire cover generic oral micronized progesterone, though formulary placement and cost-sharing vary. Anthem Blue Cross Blue Shield, Cigna, Harvard Pilgrim Health Care, and Ambetter (the marketplace plan administered by NH Healthy Families) all list generic micronized progesterone on their formularies as of 2026.

Typical cost-sharing on a Tier 1 or Tier 2 generic ranges from $5 to $20 per month. Some high-deductible health plans require the patient to pay the full negotiated price ($30 to $50) until the deductible is met.

Brand Prometrium, when specifically requested, usually falls on Tier 3 (preferred brand) with copays of $40 to $75, or requires prior authorization demonstrating generic intolerance. A 2020 review in Menopause found no clinically meaningful differences in efficacy or side effects between brand and generic micronized progesterone, so insurers rarely approve brand without documentation of generic failure.

New Hampshire's insurance division does not mandate coverage of any specific hormone therapy drug, but the state does require that plans sold on the marketplace cover preventive services consistent with USPSTF recommendations. Since progesterone use during estrogen therapy is a safety measure rather than a screening service, it falls outside preventive coverage mandates. Coverage depends entirely on the plan's pharmacy formulary.

Patients who are denied coverage should file a formulary exception request. The AACE/ACE 2017 guidelines on menopause management provide supporting language for the medical necessity of micronized progesterone specifically (rather than synthetic progestins), citing its neutral-to-favorable metabolic profile.

Is Compounded Progesterone Legal in New Hampshire?

Yes. Compounded oral micronized progesterone is legal in New Hampshire through licensed 503A pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions, provided they meet specific conditions: a valid prescription, patient-specific compounding (not large-scale manufacturing), and compliance with state pharmacy board regulations.

New Hampshire's Board of Pharmacy oversees compounding pharmacies within the state. Several retail pharmacies in Concord, Manchester, Nashua, and the Seacoast region offer compounded hormone preparations. The $25 per month average reflects a 30-day supply of micronized progesterone in a standard oral capsule form.

One important distinction. 503A compounding (patient-specific, prescription-required) is legal. 503B outsourcing facilities can also supply compounded progesterone, but these operate under different federal oversight and typically serve clinics rather than individual patients. Both pathways are available in New Hampshire.

The FDA's compounding quality page provides current guidance on the regulatory framework. Patients choosing compounded progesterone should confirm that their pharmacy holds a current New Hampshire compounding license and follows USP 795 and USP 797 standards for non-sterile and sterile preparations, respectively.

How to Get Oral Micronized Progesterone via Telehealth in NH

New Hampshire permits telehealth prescribing of oral micronized progesterone without geographic restriction within the state. Since HB 1623 (signed 2020) and subsequent pandemic-era expansions that were made permanent, prescribers licensed in New Hampshire can evaluate patients and write prescriptions via synchronous audio-video visits.

This means a patient in Berlin, Keene, or Littleton can consult with a provider in Concord or even another state (provided the prescriber holds an NH license or practices under the Interstate Medical Licensure Compact) and receive a progesterone prescription sent electronically to any NH pharmacy.

The practical workflow is simple. Schedule a telehealth visit with an OB-GYN, endocrinologist, or primary care provider. Discuss menopausal symptoms and HRT goals. If micronized progesterone is indicated, the prescription goes to the pharmacy of your choice. Total visit cost through telehealth platforms ranges from $50 to $150 without insurance, comparable to an in-person copay for many plans.

A 2023 study in the Journal of Women's Health found that telehealth-initiated HRT had equivalent safety and adherence outcomes compared to in-person prescribing across a 12-month follow-up period. The study followed 1,247 women across multiple states, including patients in rural areas with limited access to menopause specialists.

Discount Programs and Savings Cards

Several pathways can reduce the cost of oral micronized progesterone below the $45 retail average in New Hampshire.

Manufacturer savings cards. AbbVie (which markets brand Prometrium) offers a savings card that can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients. The card does not apply to government insurance (Medicaid, Medicare, Tricare). Patients fill out an enrollment form online or receive a card from their prescriber's office.

Pharmacy discount programs. GoodRx, RxSaver, and similar platforms show real-time pricing at NH pharmacies. Generic micronized progesterone 200 mg #30 capsules frequently appears at $15 to $30 through these programs at Walmart, Costco (no membership required for pharmacy), and independent pharmacies. Prices fluctuate, so checking multiple platforms before filling is worthwhile.

Mail-order pharmacy. Many insurance plans offer 90-day supplies through mail-order at reduced copays. A $10 copay for 30 days often becomes $20 for 90 days through mail-order, cutting the effective monthly cost in half.

Patient assistance programs. For uninsured patients with household income below 200% of the federal poverty level, NeedyMeds and RxAssist maintain databases of manufacturer and foundation assistance programs. AbbVie's patient assistance program covers brand Prometrium for qualifying individuals.

A 2021 analysis in the American Journal of Obstetrics and Gynecology found that out-of-pocket costs were the single strongest predictor of HRT discontinuation within the first year, with each $10 increase in monthly copay associated with a 9% increase in discontinuation risk [3]. Minimizing cost is not just a financial issue. It directly affects whether patients maintain the endometrial protection that makes estrogen therapy safe.

Cyclic vs. Continuous Dosing and Cost Implications

The dosing schedule affects monthly cost. Cyclic dosing (200 mg for 12 days per 28-day cycle) uses 12 capsules per month. Continuous dosing (100 mg or 200 mg nightly) uses 30 capsules. At the generic cash-pay price, cyclic dosing costs roughly $18 per month compared to $45 for continuous dosing.

The 2022 NAMS position statement on hormone therapy notes that both cyclic and continuous regimens effectively protect the endometrium when used with standard-dose estrogen therapy. Cyclic dosing produces a predictable withdrawal bleed in most women, while continuous dosing aims for amenorrhea after an initial 3 to 6 month adjustment period during which irregular spotting is common.

Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women's Health and medical director of the North American Menopause Society, has stated: "The choice between cyclic and continuous progesterone should be individualized based on the patient's preference regarding withdrawal bleeding, her time since menopause, and her symptom profile."

For cost-conscious patients, cyclic dosing can cut progesterone expenses by 60% without compromising endometrial safety. This is a conversation worth having with your prescriber.

What the PEPI Trial Means for Your Prescription

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial remains the landmark study that established oral micronized progesterone as a preferred progestogen for HRT. Published in JAMA in 1996, PEPI (N=875) randomized postmenopausal women to conjugated equine estrogens alone, CEE plus medroxyprogesterone acetate (cyclic or continuous), CEE plus oral micronized progesterone (200 mg, 12 days per cycle), or placebo [1].

The results favored micronized progesterone on several metabolic endpoints. HDL cholesterol increased by 4.1 mg/dL in the micronized progesterone group versus a 2.4 mg/dL decrease with continuous MPA (P<0.001). Endometrial hyperplasia rates were 0% in the micronized progesterone arm at 36 months, identical to the MPA arms. Both progestogens provided complete endometrial protection, but micronized progesterone did so without blunting the HDL benefit of estrogen.

This metabolic advantage is why the Endocrine Society, NAMS, and AACE all recognize micronized progesterone as a preferred option. For New Hampshire patients weighing their options, the clinical evidence supports requesting micronized progesterone specifically, even if a plan's default formulary position favors MPA.